[A serial study of in cytogenetic change and morphology on the tetra-arsenic tetra-sulfide treatment in untreated or recurrent acute promyelocytic leukemia].
OBJECTIVE
To study the morphologic and cytogenetic change in acute promyelocytic leukemia (APL) patients during the tetra-arsenic tetra-sulfide (TATS) treatment and the mechanism of TATS.


METHODS
The bone marrow cells of 13 newly diagnosed and 7 recurrent APL patients were studied through FISH and morphology during the TATS treatment by special and repeated marrow culture.


RESULTS
Cytomorphological study of 8 cases (6 untreated and 2 recurrent) showed that TATS could differentiate APL cells forward to mature granulocytes. There was obvious correlation between the reduced t (15; 17) positive cells and the reduced APL cells (r range 0.7298 - 0.9989). Except one patient with t (11; 17), 19 (13 untreated and 7 recurrent) with translocation t (15; 17) achieved clinical CR including 16 who achieved cytogenetic CR.


CONCLUSIONS
TATS has a differentiation-inducing effect on untreated and recurrent APL, with haematological CR and cytogenetic CR achieved. Measurement of t (15; 17) positive cells by FISH technique can reflect the change of APL cells objectively.
Liu
Hui
H
Cytogenetic Laboratory, Instituste of Hematology, People's Hospital, Beijing University, Beijing 100044, China.
Qiu
Jing-ying
JY
Lu
Dao-pei
DP
Hong
Bo
B
Shi
Hui-lin
HL
Shi
Yan
Y
Dang
Hui
H
He
Qi
Q
D000328:Adult; D001152:Arsenicals / Q000627:therapeutic use*; D001853:Bone Marrow / Q000473:pathology; D002884:Chromosomes, Human, Pair 15; D002886:Chromosomes, Human, Pair 17; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D013440:Sulfides / Q000627:therapeutic use*; D014178:Translocation, Genetic
D001152:Arsenicals; D013440:Sulfides; C534735:tetraarsenic tetrasulfide